Alphatec (ATEC) Projected to Post Earnings on Thursday

Alphatec (NASDAQ:ATEC) is anticipated to post its Q1 2025 quarterly earnings results after the market closes on Thursday, May 1st. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $167.57 million for the quarter.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.04). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The company had revenue of $176.79 million during the quarter, compared to analysts’ expectations of $172.74 million. On average, analysts expect Alphatec to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Alphatec Stock Down 3.6 %

ATEC stock opened at $11.09 on Tuesday. Alphatec has a 1-year low of $4.88 and a 1-year high of $13.79. The business has a fifty day moving average price of $10.41 and a 200-day moving average price of $9.76. The stock has a market capitalization of $1.60 billion, a P/E ratio of -8.66 and a beta of 1.20. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on ATEC shares. Barclays raised their price objective on Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, January 22nd. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research note on Monday, April 14th. Needham & Company LLC reissued a “buy” rating and issued a $16.00 price target on shares of Alphatec in a report on Thursday, February 27th. StockNews.com upgraded shares of Alphatec from a “sell” rating to a “hold” rating in a research note on Friday, February 28th. Finally, Piper Sandler increased their price objective on Alphatec from $12.00 to $13.00 and gave the company an “overweight” rating in a report on Thursday, February 27th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $17.67.

Insider Transactions at Alphatec

In related news, EVP David Sponsel sold 12,946 shares of the firm’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $10.73, for a total transaction of $138,910.58. Following the completion of the sale, the executive vice president now directly owns 722,128 shares in the company, valued at approximately $7,748,433.44. This trade represents a 1.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Patrick Miles sold 12,691 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $10.64, for a total transaction of $135,032.24. Following the completion of the sale, the chief executive officer now directly owns 5,857,603 shares of the company’s stock, valued at approximately $62,324,895.92. This trade represents a 0.22 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 272,113 shares of company stock worth $3,121,225 in the last ninety days. Insiders own 22.80% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.